RE
ESPR

RBC Europe’s Esperion Therapeutics ESPR Stock Holding History

RBC Europe’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,185
Closed -$30.8K – 1195
2020
Q4 		$30.8K Hold
1,185
– – ﹤0.01% 621
2020
Q3 		$44K Buy
1,185
+284
+32% +$11.2K ﹤0.01% 481
2020
Q2 		$46.2K Hold
901
– – ﹤0.01% 460
2020
Q1 		$28.4K Buy
+901
New +$47.5K ﹤0.01% 484

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

RBC Europe's ESPR Position: Q1 2021 in Review

RBC Europe sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 1,185 shares — an estimated $30.8K sold.

RBC Europe first reported a position in ESPR in Q1 2020 and held it in 4 quarters. The position peaked at $46.2K in Q2 2020. 155 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • RBC Europe reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • RBC Europe sold 1,185 Esperion Therapeutics shares in Q1 2021, an estimated $30.8K.
  • RBC Europe first reported a position in Esperion Therapeutics in Q1 2020 and held it in 4 quarters.
  • RBC Europe's Esperion Therapeutics position peaked at $46.2K in Q2 2020.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.